Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
By Day 26, patients had lost an average of 6.1 percent of body weight, deepening to 9.1 percent by Day 54, while waist circumference fell by nearly four inches over the same period
Orforglipron's signaling profile has been characterized in the peer-reviewed publication in Science Translational Medicine in 2024, which reported that orforglipron demonstrates a Gs-biased signaling profile with relatively reduced beta-arrestin recruitment compared to peptide agonists
Certified Each vial is independently evaluated for quality and purity through a government approved laboratory in the USA USA Sourced - USA Tested Precision-focused research materials designed to support consistent laboratory applications
PubMed laboratory research record [PMID: 40487375] PubMed record related to this compound for laboratory literature review
Endocrinology 80 , 975978 (1967)
